Valuation : Immuneering Corporation

Market Cap 312M 268M 252M 230M 430M 29.56B 432M 2.99B 1.16B 15.11B 1.17B 1.15B 48.09B P/E 2026 *
-4.31x
P/E 2027 * -3.84x
Enterprise Value 312M 268M 252M 230M 430M 29.56B 432M 2.99B 1.16B 15.11B 1.17B 1.15B 48.09B EV / Sales 2026 *
-
EV / Sales 2027 * 16x
Free-Float
86.18%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Immuneering Corporation

1 day-1.35%
1 week-1.34%
Current month-4.11%
1 month+5.63%
3 months+21.76%
6 months-14.86%
Current year-27.28%
1 week 4.68
Extreme 4.685
5.1
1 month 4.51
Extreme 4.51
5.43
Current year 3.86
Extreme 3.86
8.48
1 year 3.86
Extreme 3.86
10.08
3 years 1
Extreme 1
10.08
5 years 1
Extreme 1
33.25
10 years 1
Extreme 1
33.99
Manager TitleAgeSince
Chief Executive Officer 44 2008-01-31
Director of Finance/CFO 61 2026-07-15
Chief Tech/Sci/R&D Officer - 2023-07-31
Director TitleAgeSince
Chairman 81 2007-12-31
Director/Board Member 44 2008-01-31
Director/Board Member 72 2021-04-26
Date Insider Type Main position Quantity % Market Cap. Importance
7/16/26 Other

Chief Financial Officer

225,000 0.3478%
7/16/26 Free

Chief Financial Officer

650,000 1.0047%
3/13/26 Free

Head of Human Resources

3,628 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%-1.34%-19.58%-40.19% 312M
+2.02%+1.01%+45.58%+104.91% 67.82B
-0.41%-2.30%+33.53%+78.63% 63.22B
-0.42%+3.71%-14.09%+379.89% 27.58B
-4.36%-2.29%-2.97%-17.08% 26.06B
+1.69%+0.94%+33.46%+17.80% 25.38B
+1.12%+0.84%+24.50%-17.84% 19.89B
+6.04%+0.72%+239.13%+407.95% 17.4B
-0.49%-1.85%-6.87%+546.36% 14.95B
-1.05%+3.01%+55.48%+165.04% 14.62B
Average +0.29%+1.91%+38.82%+162.55% 27.72B
Weighted average by Cap. +0.49%+1.54%+39.48%+143.86%

Financials

2026 *2027 *
Net sales - 19.5M 16.77M 15.77M 14.39M 26.86M 1.85B 27M 187M 72.31M 945M 73.22M 71.63M 3.01B
Net income -74.1M -63.71M -59.94M -54.7M -102M -7.03B -103M -710M -275M -3.59B -278M -272M -11.43B -85.92M -73.87M -69.5M -63.42M -118M -8.15B -119M -823M -319M -4.16B -323M -316M -13.25B
Net Debt - -
Logo Immuneering Corporation
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.
Employees
57
Date Price Change Volume
26-09-08 US$4.789 -0.64% 653,304
26-09-04 US$4.820 -4.37% 1,000,331
26-09-03 US$5.040 +0.40% 424,432
26-09-02 US$5.020 +3.51% 678,701
26-09-01 US$4.850 -2.81% 435,184
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.820USD
Average target price
17.17USD
Spread / Average Target
+256.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMRX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!